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The brain incorporates and coordinates information based on the hormonal environment,
receiving information from peripheral tissues through the circulation. Although it was
initially thought that hormones only acted on the hypothalamus to perform endocrine func-
tions, it is now known that they in fact exert diverse actions on many different brain regions
including the hypothalamus. Ghrelin is a gastric hormone that stimulates growth hormone
secretion and food intake to regulate energy homeostasis and body weight by binding
to its receptor, growth hormone secretagogues–GH secretagogue-receptor, which is most
highly expressed in the pituitary and hypothalamus. In addition, ghrelin has effects on learn-
ing and memory, reward and motivation, anxiety, and depression, and could be a potential
therapeutic agent in neurodegenerative disorders where excitotoxic neuronal cell death
and inﬂammatory processes are involved.
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GHRELIN AND GROWTH HORMONE SECRETAGOGUES
Ghrelin is a 28-amino acid peptide that is esteriﬁed with octanoic
acid on serine 3 and is mainly released from the oxyntic cells of the
stomach mucosa. It was discovered based on its ability to stimulate
growth hormone (GH) release by activating the GH secretagogue-
receptor (GHSR-1a) in the pituitary (Kojima et al., 1999; Date
et al., 2000). Ghrelin has many other peripheral actions includ-
ing direct effects on exocrine and endocrine pancreatic functions,
carbohydratemetabolism, the cardiovascular system,gastric secre-
tion, stomach motility, and sleep (Van der Lely et al., 2004; Ghigo
et al., 2005; Kojima and Kangawa, 2005).
One of the most studied functions of ghrelin is its orexigenic
properties, which has prompted the investigation of this hor-
mone as a target for the treatment of obesity (Foster-Schubert
and Cummings, 2006; Zorrilla et al., 2006). Ghrelin promotes
feeding, weight gain, and adiposity by acting both at central and
peripheral targets (Tschop et al., 2001a; Wren et al., 2001) with
an inverse correlation between circulating ghrelin levels and body
weight (Tschop et al., 2000). Moreover, lack of ghrelin in KO mice
(Wortley et al., 2005) or ghrelin signaling in growth hormone
secretagogues (GHS)–R1a KO mice (Zigman et al., 2005) pro-
tects against diet-induced obesity (DIO). Indeed, a vast number
of studies point to ghrelin as an important hormonal signal pro-
moting feeding and regulatingmetabolism in humans and rodents
(Cummings et al., 2001; Tschop et al., 2001b; Drazen et al., 2006).
Ghrelin originates from the proteolytic cleavage of pre-pro-
ghrelin and pro-ghrelin. Posttranslational acylation of pro-ghrelin
by the ghrelin O-acyltransferase (GOAT) enzyme is required for
its activation of GHS–R1a (Figure 1). GOAT is found mostly in
the stomach (Yang et al., 2008), acylating newly synthesized pro-
ghrelin, with ghrelin exists as two forms in the plasma, acylated
ghrelin and des-acylated ghrelin. Although des-acyl ghrelin is
found at high concentrations in the plasma, it neither activates
GHSR-1a nor causes GH release in vivo or in vitro (Kojima
et al., 1999; Bednarek et al., 2000; Hosoda et al., 2000; Toshinai,
2006). However, it is now thought that des-acylated ghrelin may
exert physiologically relevant effects through as yet unidentiﬁed
receptors.
Growth hormone secretagogues (GHS) are metenkephalin-
derived synthetic oligopeptides and non-peptidyl molecules that
activate the GHS–R1a (Davenport et al., 2005). Multiple peptidyl
and several non-peptidyl analogs of ghrelin have been developed
and functionally assessed over the last three decades. Unlike ghre-
lin, they do not require acylation to activate GHS–R1a and are not
known to be GOAT substrates. These synthetic analogs can exhibit
partial agonism (e.g., stimulation of appetite, but not GH release
and vice versa), antagonism, and inverse agonism despite similar
GHS–R1a binding afﬁnities (Holst et al., 2004, 2006; Halem et al.,
2005; Veldhuis and Bowers, 2010).
GHRELIN RECEPTOR
The ghrelin receptor, GHS–R1a, is a G protein-coupled 7-
transmembrane receptor that was ﬁrst cloned from the pituitary
and hypothalamus. It belongs to a family of receptors operating
via the Gq-phospholipase C signaling pathways (Howard et al.,
1996). Other signaling pathways involved are ERK1/2, the PLC–
PKC pathway and Raf–MEK–MAPK. Ghrelin acts on GHS–R1a
to increase intracellular Ca2+ via the guanine nucleotide binding
protein q phospholipase C (Gq-PLC) pathway (Kojima and Kan-
gawa, 2005). Through the α-subunit of GHS–R1a, activation of
the PLC–protein kinase C pathway and Raf–MEK–MAPK occurs
(Chung et al., 2007). Ghrelin also transactivates the tyrosine kinase
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FIGURE 1 | Schematic representation of the posttranslational processing
of ghrelin. A signal peptide peptidase cleaves the signal sequence. Acylation
of pro-ghrelin occurs by means of ghrelin O-acyl transferase (GOAT), which is
located in the ER compartment and mediates the translocation of
octanoyl-CoA. Once the pro-ghrelin precursor reaches the trans-Golgi
compartment, it is cleaved by PC1/3 prohormone convertase. Different forms
of ghrelin are released to the circulation: acylated, unacylated, and other
shorter forms.
receptor via the β- and γ-subunits, leading to activation of MAPK
via the Ras–Raf–MEK pathway (Nanzer et al., 2004). Furthermore,
ghrelin and des-acylated ghrelin have been shown to exert their
effects through stimulation of c-AMP-mediated PKA pathways
(Granata et al., 2007). The anti-apoptotic effects of ghrelin and
des-acylated ghrelin are mediated via the MAPK and PI3K sig-
naling pathways, with Akt downstream effectors being involved in
many of these effects. Akt can phosphorylate effector proteins at
the membrane or cytoplasmic levels, including for example GSK-
3β. It can also act as a transcription factor or phosphorylate other
transcription factor at the nuclear level (Song et al., 2005).
This receptor is found at highest concentrations in the pituitary
andhypothalamus (Howard et al., 1996) and acts primarily at these
sites to stimulate GH release, induce a positive energy balance
by stimulating food intake and decrease adipose usage through
GH-independent mechanisms (Date et al., 2000). The abundant
expression of GHS–R1a in the hypothalamus highlights its impor-
tant role in energy metabolism. This receptor is highly expressed
in agouti-related peptide/neuropeptide Y neurons in the arcuate
nucleus and neurons in the ventromedial nucleus that express fatty
acid synthase (Bennet et al., 1997; Guan et al., 1997; Tannenbaum
et al., 1998; Willesen et al., 1999; Mitchell et al., 2001; Nogueiras
et al., 2004; Smith et al., 2005; Zigman et al., 2006; López et al.,
2008; Lage et al., 2010). There is also abundant GHSR-1a expres-
sion in other neuronal populations (Kohno et al., 2003) including
the dentate gyrus of the hippocampus, theCA2 andCA3 regions of
the hippocampus, the substantia nigra (SN), the ventral tegmental
area (VTA), and various thalamic and brainstem nuclei, including
the dorsal raphe nucleus (DRN; Shiiya et al., 2002). GHSR-1a
has recently been identiﬁed in the thoracic, lumbar and sacral
regions of the spinal cord (Ferens et al., 2010), and expressed in
sympathetic and autonomic preganglionic neurons.
ANTI-APOPTOTIC ACTIONS OF GHRELIN, DES-ACYLATED
GHRELIN AND GH SECRETAGOGUES
Ghrelin protects several cell types such as adipocytes (Kim et al.,
2004) osteoblasts (Kim et al., 2005), cardiomyocytes, and endothe-
lial cells (Baldanzi et al., 2002) by inhibiting apoptotic stimuli.
Ghrelin, even at rather low doses (10−13 M), protects hypo-
thalamic neuronal cells from cell death by inhibiting apoptosis
(Chung et al., 2007). It has been reported to have protective
effects against a variety of stimuli including ischemia/reperfusion
(Chang et al., 2004; Konturek et al., 2006), alendronate (Iseri et al.,
2005), serum deprivation (Kim et al., 2004), doxorubicin (Bal-
danzi et al., 2002), and TNF-α (Kim et al., 2005). At least some
of the neuroprotective effects of ghrelin appear to be mediated
through activation of GHS–R1a, as the speciﬁc receptor antago-
nist D-Lys-3-GH-releasing peptide (GHRP-6) completely blocks
the protective effects of ghrelin against oxygen–glucose depriva-
tion (OGD) insult. In contrast, Baldanzi et al. (2002) reported
that in cardiomyocytes ghrelin exhibits an anti-apoptotic effect
through binding to a novel, unidentiﬁed receptor that is distinct
from GHS–R1a.
Multiple signaling pathways are involved in ghrelin-induced
ERK1/2 activation, and the anti-apoptotic effects of ghrelin
are mediated via the PI3K, PKC, and PKA signaling pathways.
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Ghrelin activates ERK1/2 in 3T3-L1 adipocytes (Kim et al., 2004),
osteoblasts (Kim et al., 2005), cardiomyocytes, and endothelial
cells (Baldanzi et al., 2002). This activation is believed to be an
important mechanism to limit ischemic damage in hypothala-
mic neuronal cells (Jiang et al., 2002). A selective inhibitor of
ERK1/2, PD98059, inhibits ghrelin-induced phosphorylation of
ERK1/2 and the anti-apoptotic activities of ghrelin. On the other
hand, ghrelin has been shown to exert its effects in various cells
through stimulation of c-AMP-mediated PKA pathways (Kohno
et al., 2003). Pretreatment with a PI3K inhibitor (wortmannin),
PKC inhibitor (GF109203X), or PKA inhibitor (H89) signiﬁcantly
attenuates ghrelin-induced phosphorylation of ERK1/2 and the
anti-apoptotic effects of ghrelin (Chung et al., 2007).
Des-acylated ghrelin protects cortical neurons from the apop-
totic stimuli induced by OGD insult. Moreover, both types of
ghrelin inhibit OGD-induced apoptosis even when administered
4 h after an OGD insult. This suggests that these peptides may
have the ability to attenuate disease progression through activation
of MAPK and PI3K/Akt signaling pathways even when adminis-
tered sometime after the insult has occurred (Chung et al., 2011).
Des-acylated ghrelin also stimulates PI3K/Akt pathways,with both
ghrelin and des-acylated ghrelin capable of altering the status of
the Bcl-2 family of proteins, inhibiting cytochrome c release and
caspase-3 activity and promoting the survival of cortical neurons
(Chung et al., 2008). Some studies have also reported the pro-
tective effects of des-acylated ghrelin on systemic tissues (Cassoni
et al., 2001; Baldanzi et al., 2002; Nanzer et al., 2004; Maccarinelli
et al., 2005; Delhanty et al., 2006; Filigheddu et al., 2007; Granata
et al., 2007).
The neuroprotective effects of des-acylated ghrelin do not
appear to be mediated through activation of GHS–R1a, as antag-
onism of this receptor fails to block the protective effect of
des-acylated ghrelin against OGD insult. This is to be expected
as des-acylated ghrelin is reported to neither activate nor bind
GHS–R1a (Kojima et al., 1999); thus, the existence of a separate
speciﬁc receptor for des-acylated ghrelin is suspected.This hypoth-
esis is supported by the observation by Toshinai et al. (2006) in
which des-acylated ghrelin, but not acylated ghrelin stimulated
food intake in GHS–R1a-deﬁcient mice, as well as by other studies
(Baldanzi et al., 2002; Muccioli et al., 2004; Gauna et al., 2006;
Filigheddu et al., 2007; Granata et al., 2007). Taken together, the
ﬁndings provide evidence that ghrelin, regardless of its acylation,
may function as a survival factor for neuronal cells and offer a new
perspective on the potential role of these peptides in neuronal
injury.
THE NEUROPROTECTIVE ACTIONS OF GHRELIN AND GHS
As explained above, ghrelin stimulates the ERK1/2 and PI3K/Akt
pathways through activation of GHS–R1a, which has been impli-
cated in the regulation of cell survival (Figure 2; Datta et al.,
1999; Pearson et al., 2001; Chung et al., 2007, 2008). Systemic
administration of GHRP-6, a GHS, increases expression of pro-
teins involved in cell survival or neuroprotection (Frago et al.,
2002, 2005; Figure 3). Treatment of adult male rats with GHRP-6
for 1week signiﬁcantly increases insulin-like growth factor (IGF)-I
mRNA levels in the hypothalamus, cerebellum, and hippocam-
pus and this is associated with increased phosphorylation of Akt
and Bad, with no change in MAPK or GSK-3. This suggests that
GHRP-6 activates phosphatidylinositol kinase intracellular path-
ways involved in cell survival in response to growth factors and that
this could be mediated through stimulation of local IGF-I produc-
tion. Indeed, the anti-apoptotic protein Bcl-2 was augmented in
these same areas, with no change in the pro-apoptotic protein
Bax. Moreover, GHRP-6, reduces cerebellar cell death in aged rats
and this phenomenon appears to be mediated via the stimula-
tion of IGF-I production, which in turn inhibits the activation of
caspases 9 and 3 (Pañeda et al., 2003). Other studies show that
ghrelin exerts its neuroprotective effects through stimulation of
the protein kinase A and C pathways (Chung et al., 2007). Taken
together, these ﬁndings suggest that multiple signaling pathways
are involved in ghrelin-mediated protection.
Table 1 shows the effect of ghrelin, des-acyl ghrelin, GHS, and
antagonists in different diseases.
EXCITOTOXICITY
Excitotoxic brain damage is one of the major mechanisms by
which neurons die in the adult central nervous system (CNS).
l-Glutamate is the principal excitatory neurotransmitter in the
mammalian CNS and under pathological conditions such as
trauma, stroke, epilepsy, or hypoglycemia, excess release of l-
Glutamic acid and other excitatory amino acids can lead to exci-
totoxic lesions in the brain due to over-excitation of nerve cells
(Gill and Pulido, 2001). Over-activation of two major subtypes
of ionotropic glutamate receptors, AMPA and NMDA, initiates a
cascade of events involving protease activation and mitochondrial
dysfunction that can result in cell death (Seeburg, 1993; Glazner
andMattson,2000). Systemic administration of monosodiumglu-
tamate (MSG) induces apoptosis of hypothalamic and cerebellar
neurons, which is associated with activation of caspases 9 and
7. GHRP-6 is capable of preventing this glutamate-induced cell
death in both the hypothalamus and cerebellum (Delgado-Rubín
de Célix et al., 2006). Moreover, MSG also induces cell death in
the neuronal cell line RCA-6 by activating the intrinsic pathway
of apoptosis through caspase-9 and -3/7 (Delgado-Rubín et al.,
2009), which is in agreement with previous studies indicating that
neurons and the neuroblastoma cell lines B50 and SH-SY5Y use
the intrinsic pathway to undergo apoptotic cell death in response
to excitotoxicity (Henshall et al., 2001; Mattson, 2003). However,
although GHRP-6 partially inhibits MSG-induced cell death in
RCA-6 neurons, it does not modify caspase-9 or -3/7 activities
(Delgado-Rubín et al., 2009). Indeed,MSGalso activates a caspase-
independent pathway in these cells. Similar results showing two
mechanisms of MSG-induced cell death have been reported in
primary cortical neurons where MSG activates calpain, caspase-
3 and the translocation of apoptosis-inducing factor (AIF) from
the mitochondria to the cytosol and nuclei (Zhang and Bhavnani,
2006). Indeed,AIF plays an important role in caspase-independent
mechanisms of cell death and is reported to be a key factor in neu-
ronal death during excitotoxicity (Cheung et al., 2005). In RCA-6
neurons MSG promotes a perinuclear aggregation of AIF and
this change in cellular localization is impeded by the presence
of GHRP-6. As the insertion of Bax in the inner mitochondr-
ial membrane is necessary for AIF release (Selznick et al., 2000;
Arnoult et al., 2003), the GHRP-6-induced increment of Bcl-2,
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FIGURE 2 | Summary of intracellular mechanisms mediating the
neuroprotective effects of ghrelin. GHS–R1a activation result in release of
intracellular calcium and protein kinase C (PKC) activation that leads to the
stimulation of mitogen-activated protein kinases (MAPKs) pathway. The
generation of phosphatidylinositol phosphates PIP3 and PIP2 induces the
protein inositol 3 kinase (PI3K)/Akt pathway. MAPK and Akt stimulate cell
proliferation and inhibit apoptosis. Ghrelin also regulates hypothalamic
AMP-activated protein kinase (AMPK), phosphorylating (pAMPK), and
activating it, which in turn phosphorylates and inactivates acetyl-CoA
carboxylase (ACC), decreasing the cytoplasmic pool of malonyl-CoA, which
promotes the generation of reactive oxygen species (ROS), which are
buffered by uncoupling protein 2 (UCP-2).
FIGURE 3 | Diagram summarizing the GHRP-6 survival actions
proposed against monosodium glutamate (MSG) excitotoxicity. MSG
activates JNK or p38, caspases and stimulates the translocation of
apoptosis inducing factor (AIF). Growth hormone-releasing peptide
(GHRP)-6 prevents cell death by inducing Bcl-2 and nuclear factor-kappa B
(NF-κB) that results in the blockage of AIF translocation and caspase and
PARP activation. Insulin-like growth factor (IGF)-I prevents cell death by
blocking caspase activation.
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Table 1 | Summary of the neuroprotective effects of ghrelin, des-acyl ghrelin, and synthetic antagonists and agonists of the ghrelin receptor.
Ghrelin Des-acyl ghrelin GHS Antagonists
Excitotoxicity Prevents kainic acid and pilocarpine-induced
excitotoxicity in hippocampal neurons
Not determined Prevents glutamate-induced
apoptosis in the hypothalamus
and cerebellum
Not
determined
Parkinson’s
disease
Increase tyrosine hydroxylase in midbrain
and dopamine turnover induced in the
striatum. Reduce dopamine cell loss induced
by MPTP. Inhibits microglia activation after
MPTP administration
Not determined Not determined Not
determined
Stroke and
ischemia
Neuroprotection in the forebrain reducing
infarct volume and cell death. Protects loss
of CA1 and CA3 neurons after IR. Protects
oxygen and glucose-deprived cells in
hypothalamic neurons. Protects cortical
neurons from injury induced by transient
focal cerebral IR
Protects hippocampus from
IR reducing infarct volume.
Protect cortical neurons from
injury induced by transient
focal cerebral IR
Hexarelin reduces infarct size
following focal cerebral ischemia
and improves neuronal survival
in vitro
Reverses
neuroprotec-
tion effects
of ghrelin,
but not of
des-acyl
ghrelin
Epilepsy Anti-epileptic effects in
pentylenetetrazole-injected rats. Decreases
oxidative stress in hippocampal neurons. In
pilocarpine models of epilepsy attenuates
CA1 and CA3 hippocampal neuronal loss.
Attenuates kainic acid-induced neuronal
death in CA1 and CA3 hippocampal regions.
Anticonvulsant effect in animal seizure
models
Not determined Not determined Not
determined
Spinal cord
injuries
Improves functional recovery by inhibiting
apoptosis and enhancing neurogenesis
Not determined Not determined Not
determined
Encephalomyelitis Reduces severity and levels of
pro-inﬂammatory cytokines and activated
microglia
Not determined Not determined Not
determined
Diabetes Decreases cell death in the anterior pituitary Not determined In combination with insulin,
GHRP-6 attenuates cell death in
hypothalamus and cerebellum
Not
determined
GHRP-6, growth hormone-releasing peptide 6; MPTP IR.
and hence its ability to complex with Bax, could block the release
of AIF to the cytosol and its translocation to the nucleus (Susin
et al., 1999).
Administration of kainic acid (KA) induces a sequence of
altered behavioral events characterized by epileptiform seizures
(Ben-Ari et al., 1980; Sperk, 1994),which are followed by neurode-
generation in speciﬁc brain regions, including the hippocampus,
piriform cortex, thalamus, and amygdala. In the hippocampus, the
CA3 pyramidal cells and interneurons in the hilus of the dentate
gyrus are the most vulnerable, followed by CA1 pyramidal cells
(Coyle, 1983; Sperk et al., 1985). Ghrelin could have a neuropro-
tective role in hippocampal neurons against KA-induced excito-
toxicity, as it protects hippocampal neurons against pilocarpine-
induced seizures (Xu et al., 2009) via activation of the PI3K/AKT
pathway and inhibition of the mitochondrial apoptotic pathway.
Excitotoxic neuronal damage evoked by excessive or prolonged
activation of excitatory amino acid receptors is recognized as an
importantmechanism in several neurodegenerative disorders such
as stroke, traumatic brain injury, amyotrophic lateral sclerosis,
Parkinson’s disease (PD), Huntington’s disease, and Alzheimer’s
disease (AD; Doble, 1999; Salinska et al., 2005).
PARKINSON’S DISEASE
Parkinson’s disease is characterized by the progressive degen-
eration of dopaminergic neurons that project from the SN to
the dorsal striatum. The GHS–R1a is abundantly expressed in
dopaminergic neurons in the SN (Guan et al., 1997; Zigman
et al., 2006) with ghrelin increasing tyrosine hydroxylase expres-
sion in themidbrain anddopamine turnover in the dorsal striatum
(Andrews et al., 2009). Sub-acute MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) administration, which selectively kills
dopaminergic neurons in the SN, is suggested to be a model for
PD (Przedborski et al., 2000). MPTP is taken up by dopamin-
ergic neurons and leads to impairment in mitochondrial func-
tion. The subsequent energy failure with ATP depletion increases
the formation of free radicals (Schmidt and Ferger, 2001) and
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cytochrome c release (Gómez et al., 2001; Singh andDikshit, 2007).
Intraperitoneal injection of ghrelin reduces dopamine cell loss in
the SN in mice treated with MPTP (Andrews et al., 2009), most
likely through attenuation of MPTP-induced caspase-3 activation
by regulating intracellular apoptotic signaling molecules, such as
Bcl-2 and Bax (Jiang et al., 2008). MPTP is known to decrease
Bcl-2 and increase Bax in the striatum (Youdim and Arraf, 2004),
thereby tilting the balance toward apoptosis. Ghrelin-treated cells
have an increased Bcl-2/Bax ratio, decreased cytochrome c release,
and inhibition of caspase-3 activation; thus, rescuing SNpars com-
pacta (SNpc) neurons from MPTP-induced toxicity (Youdim and
Arraf, 2004).
Increased microglia activation,which participates in the patho-
genesis of PD, is inhibited by ghrelin injection in the SN after
MPTP administration (Jiang et al., 2008). The neuroprotective
effects of ghrelin on MPTP-induced nigrostriatal dopamine dys-
function involve the activation of uncoupling protein (UCP)-
2-dependent mitochondrial respiration, suppression of reactive
oxygen species (ROS) production, and mitochondrial biogenesis
(Andrews, 2011), but only if mice remained fasted after ghrelin
injection. Considering that matrix metalloproteinase-3 (MMP-3)
plays a pivotal role in dopaminergic neurodegeneration in PD
(Kim et al., 2005, 2007) and ghrelin suppresses MPTP-induced
MMP-3 expression (Andrews, 2011), ghrelin may mediate the
inhibition of MMP-3 expression.
In conclusion, ghrelin can antagonize MPTP-induced neuro-
toxicity of nigral dopaminergic neurons in vivo through a GHS-R
1a mediated anti-apoptotic effect. If ghrelin can induce regener-
ation or prevent degeneration of dopaminergic neurons it could
be a potential important tool in the therapeutic strategy for treat-
ment of PD, but this possibility requires further basic and clinical
research.
STROKE AND ISCHEMIA
Recent studies highlight a neuroprotective action of ghrelin in
ischemic models of stroke, both in vivo and in vitro. In vivo rat
ischemia–reperfusion models show that ghrelin-administered ip
or intravenously (iv) elicits signiﬁcant neuroprotection in the
forebrain by reducing infarct volume and cell death (Chung
et al., 2007, 2008; Hwang et al., 2009). Both ischemic precon-
ditioning and ghrelin administration protect the hippocampus
from ischemia/reperfusion and up-regulate UCP-2, with acy-
lated and des-acylated ghrelin reported to be equally effective in
reducing infarct volume (Hwang et al., 2009). Interestingly, pre-
administration of a GHSR-1a antagonist completely reverse the
neuroprotective effect of ghrelin, but not des-acylated ghrelin,
suggesting that des-acylated ghrelin has neuroprotective effects
in ischemia independent of GHSR-1a (Chung et al., 2008; Hwang
et al., 2009). The neuroprotective mechanisms involved include
reduced apoptosis and increased mitochondrial function. Pre-
treatment of cells with acylated ghrelin prevents the induction of
apoptosis by activating ERK1/2, as well as preventing caspase acti-
vation, cytochrome C (Cyt) release and increasing the Bcl-2:Bax
ratio (Miao et al., 2007; Chung et al., 2008; Hwang et al., 2009).
Ghrelin protectsOGDcells by decreasing the generationof ROS
and stabilizing the mitochondrial membrane potential (Chung
et al., 2007), with this being dependent on the MAPK, PI3K, PKC,
andPKA signaling pathways.Consistentwith an antioxidant effect,
ghrelin has been shown to increaseUCP-2 in the hippocampus and
prevent the loss of CA1 neurons after ischemia/reperfusion (Liu
et al., 2006). Therefore, it appears that a common neuroprotec-
tive or neuromodulatory role of ghrelin in the brain could involve
UCP-2-dependent mitochondrial adaptation.
Theprotective effects of ghrelin could also involve theGH–IGF-
I axis, as IGF-I is an important neuroprotective factor in stroke and
local IGF-I production is induced by this hormone (Frago et al.,
2002, 2005). However, some in vitro studies suggest that a direct
effect of ghrelin is most likely, given that IGF-I was not increased
in vitro (Miao et al., 2007; Chung et al., 2008; Hwang et al., 2009).
In hypothalamic neuronal cells, ghrelin treatment also prevents
OGD-induced ROS generation involving Bcl-2 preventing ROS
accumulation (Sidoti-De et al., 1998) and/or shifting the cellular
redox potential to a more reduced state (Ellerby et al., 1996). The
increased levels of Bcl-2 protein in ghrelin-treated cells may both
promote cell survival and protect against ischemic oxidative stress.
Ghrelin also prevents the OGD-induced collapse of mitochondr-
ial transmembrane potential by regulating Bcl-2 family proteins
during ischemic injury (Chung et al., 2007).
Ghrelin mRNA and protein have been detected in cortical neu-
rons, suggesting a possible autocrine/paracrine mode of action of
ghrelin in the inhibition of apoptosis. The suppression of ghre-
lin expression by transfecting cells with siRNA against pre-pro-
ghrelin signiﬁcantly increased apoptosis during an OGD insult
and even in normoxic conditions (Chung et al., 2008). This obser-
vation is comparable with a report by Granata et al. (2007), in
which an antibody against ghrelin signiﬁcantly inhibited apop-
tosis in pancreatic β-cells. It should be noted that the survival
effect of endogenous ghrelin and des-acylated ghrelin could not
be distinguished because the siRNA used in this study was directed
against pre-pro-ghrelin. Chemical inhibition of both ghrelin and
des-acylated ghrelin-induced phosphorylation of Akt and ERK1/2
completely blocked the ghrelin-induced anti-apoptotic effects,
indicating that these peptides suppress OGD-induced apoptosis
in cortical neuronal cells through PI3K/Akt and ERK1/2.
The GHS hexarelin increases GSK-3β phosphorylation in post-
hypoxic-ischemic animals (Brywe et al., 2005). GSK-3β is a pro-
apoptotic protein (Eldar-Finkelman, 2002) and inhibitors of GSK-
3β reduce infarct size following focal cerebral ischemia in vivo
(Kelly et al., 2004) and improve neuronal survival in vitro (Cross
et al., 2001). Thus the PI3K/Akt-mediated inactivation of GSK-
3β is most likely at least partly responsible for the anti-apoptotic
effects of ghrelin and des-acylated ghrelin. Several transcrip-
tion factors, such as cAMP-response element-binding protein
(D’Amico et al., 2000), nuclear factor-κB (Madrid et al., 2000;
Sanchez et al., 2003), and β-catenin (Haq et al., 2003) can be reg-
ulated by GSK-3β. Ghrelin and des-acylated ghrelin-induced Akt
signaling is associated with downstream attenuation of GSK-3β
and nuclear translocation of β-catenin, targeting the Bcl-2 pro-
tein family, inhibiting cytochrome c release and caspase-3 activity,
thus inhibiting the apoptotic cascade and favoring cell survival.
Indeed, cytosolic Bcl-2 protein levels are decreased by OGD insult,
whereas treatment with des-acylated ghrelin increases Bcl-2 levels
and inhibits the OGD-induced rise in Bax levels in mitochondria,
resulting in complete normalization of the Bcl-2/Bax ratio.
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The change in the status of Bcl-2 and the Bax proteins caused by
either ghrelin or des-acylated ghrelin treatment inhibits apoptosis
and favors cell survival. It is known that the Bcl-2 protein fam-
ily tightly regulates cytochrome c release from the mitochondria
into the cytosol (Merry and Korsmeyer, 1997). After release from
the mitochondrial intermembrane space, cytochrome c forms the
apoptosome together with apoptosis-activating factor Apaf-1 and
procaspase-9, leading to activation of the initiator caspase-9 (Li
et al., 1997). Subsequent activation of downstream members of
the caspase family, including the effector caspase-3, leads to apop-
tosis (Slee et al., 1999). Cytochrome c is translocated from the
mitochondria to the cytosolic compartment after OGD insult
(Pérez-Pinzón et al., 1999) and both ghrelin and des-acylated
ghrelin prevent this translocation and the subsequent activation
of caspase-3, thus inhibiting activation of the apoptotic cascade
(Chung et al., 2007).
Intraperitoneally administered des-acylated ghrelin or ghrelin,
protects cortical neurons from injury induced by transient focal
cerebral ischemia and reperfusion in vivo, signiﬁcantly reduc-
ing infarct volumes after initiation of ischemia, at least in part
through suppression of Par-4 expression (Miao et al., 2007).
Ghrelin injected intravenously also has neuroprotective affects in
transient focal ischemia/reperfusion in rats by inhibiting apoptotic
molecules of the mitochondrial pathway and activating endoge-
nous protective molecules (Miao et al., 2007). Given that ghrelin
can pass through the blood–brain barrier (Banks et al., 2002), it
is possible that these effects, at least in part, are directly due to
ghrelin and not through other systemic changes induced by the
treatment.
EPILEPSY
Anti-epileptic effects of ghrelin have been reported in an acute
experimental epilepsy model of pentylenetetrazole-injected rats
(Obay et al., 2007). The time of onset of pentylenetetrazole-
induced seizures in rats was delayed following previous treatment
with ghrelin (Obay et al., 2007), with protein markers for oxida-
tive stress being decreased in hippocampal neurons of ghrelin-
administered rats (Obay et al., 2008). Ghrelin has also been tested
in the pilocarpine-model of epilepsy, where it attenuated CA1
and CA3 hippocampal neuronal loss by inhibiting caspase-3 acti-
vation and maintaining the Bcl-2:Bax ratio (Xu et al., 2009).
Lee et al. (2010) demonstrated that ip injection of ghrelin sig-
niﬁcantly reduces hippocampal neuronal death, the number of
TUNEL-positive cells and caspase-3 expression in associationwith
decreased seizures after KA injection, with ghrelin signiﬁcantly
attenuating KA-induced neuronal cell death in CA1 and CA3
hippocampal regions (Lee et al., 2010). In this case, the neuro-
protective effect involves suppression of microglia and astrocyte
activation, as well as suppression of inﬂammatory mediators, such
as TNF-α, interleukin-1b, and cyclooxygenase-2 (Lee et al., 2010).
Neuropeptide Y (NPY) and γ-aminobutyric acid (GABA) may
be involved in the anticonvulsant effects of ghrelin as NPY and
GABA exert anti-epileptic effects in animal seizure models (Cza-
pinski et al., 2005) and ghrelin not only enhances NPY synthesis,
but also increases GABA-ergic activity in the brain (Cowley et al.,
2003). It is well known that a majority of epileptic seizures are due
to an imbalance between the activities of inhibitory and excitatory
neurotransmitters (Sharma et al., 2007). Therefore, the stimula-
tory effect of ghrelin on NPY and GABA activities may contribute
to the anti-epileptic properties of ghrelin.
OTHER NEUROLOGICAL DISEASE MODELS
GH secretagogue-receptor is present in the spinal cord (Ferens
et al., 2010) and recent studies demonstrate that ghrelin improves
functional recovery after spinal cord injury by inhibiting apoptosis
and potentially enhancing neurogenesis (Lee et al., 2010). Ghre-
lin also restricts the development of experimental autoimmune
encephalomyelitis (EAE), an animal model of multiple sclerosis
(Theil et al., 2009). Daily ip injections of ghrelin are reported to
reduce the severity of EAEanddecrease levels of pro-inﬂammatory
cytokines and activated microglia, thus further consolidating the
anti-inﬂammatory properties of ghrelin.
Ghrelin is also reported to protect against apoptotic cell death
in cortical neurons exposed to endoplasmic reticulum (ER) stress
by activating the PI3K/Akt pathway (Chung et al., 2011). Ghrelin
targets CHOP protein via the inhibition of the PERK/eIF2α/ATF4
pathway. It is assumed that ghrelin-mediated suppression of
CHOP is associated with the exclusion of FOXO 1 from the
nucleus. Moreover, increased Akt signaling by ghrelin is associ-
ated with downstream attenuation of GSK-3β, BAD, and FOXO1.
These ﬁndings suggest that ghrelin could also function as a neuro-
protective agent in treatment of neurodegenerative diseases where
ER stress responses are involved.
DIABETES
Diabetes mellitus results in diverse complications when poorly
controlled over an extended period of time. Indeed, poor glycemic
control is not only associatedwithmetabolic and hormonal imbal-
ances (Bestetti et al., 1985), but also with an increased risk of
disorders in the CNS as a result of changes in brain metabolism,
vascular reactivity, blood–brain barrier integrity and increased
oxidative stress (Fouyas et al., 2003; Valko et al., 2007). Some of
these alterations could be due, at least in part, to increased apop-
tosis of both neurons and glial cells, as chronic hyperglycemia has
been reported to induce cell death of cortical, hippocampal and
hypothalamic neurons (Klein et al., 2004), as well as to induce
death and decrease cell proliferation of astrocytes both in vivo
and in vitro (Rungger-Brandle et al., 2000; Lechuga-Sancho et al.,
2006a,b; García-Cáceres et al., 2008).
In poorly controlled diabetes increased cell death occurs in dif-
ferent tissues and organs (Arroba et al., 2003; García-Cáceres et al.,
2008; Granado et al., 2011), with this cell loss being involved in
many of the secondary complications of diabetes. In the anterior
pituitary, lactotrophs appear to be more susceptible to diabetes-
induced death than other cell types (Arroba et al., 2003, 2005,
2006), with this process involving activation of caspase-8, the
prototypical initiator caspase of the extrinsic cell death pathway.
Ghrelin treatment decreases cell death and activation of caspase-
8 and increases Bcl-2, Hsp70, and iNOS levels in the anterior
pituitary (Granado et al., 2009).
Poorly controlled diabetes also increases cell death in the hypo-
thalamus and cerebellum (Lechuga-Sancho et al., 2006a,b; García-
Cáceres et al., 2008;Granado et al., 2009).Although treatmentwith
GHRP-6 affected cell death in these areas, it was more effective in
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combination with insulin treatment. This combined treatment
reduced the diabetes-induced-decrease in glial ﬁbrillary acidic
protein (GFAP) levels, suggesting an effect on glial cells. Thus,
GHRP-6, and possibly ghrelin, may work in concert with other
hormones such as insulin to prevent disease processes.
FUTURE PERSPECTIVES
Numerous clinical trials are underway employing both ghrelin
agonists and antagonists in diverse diseases. Simulation of appetite
and fat accumulation by ghrelin agonists in wasting diseases or
cachexia is a prime area of investigation. This hormone is currently
a therapeutical target for the development of obesity treatment, as
ghrelin antagonist should decrease appetite. In addition, the above
ﬁndings indicate that ghrelin, as well as des-acylated ghrelin, or
their analogs could function as neuroprotective agents. Further
understanding of this facet is of great importance as.
However, a number of systems may also be affected with these
treatments, as suggested by the wide distribution of the known
ghrelin receptor andwith a number of tissues and cell types known
to respond to this hormone through a yet unidentiﬁedmechanism.
Thus, it is imperative that we understand the diverse functions
of this hormone and their mechanisms of action, including the
receptors involved, in order to develop speciﬁc and safe agonists
or antagonists targeting the mechanism of interest. This will most
likely result in the identiﬁcation of new receptors for both ghrelin
and des-acyl ghrelin in the new future.
Involvement of the ghrelin system in diseases of the CNS is
unknown. However, alterations in cell metabolism are well known
to be involved in pathological processes and it is possible that
this hormone may have both direct and indirect roles in these
processes. Thus, detection of early disturbances in the ghrelin sys-
tem might possibly be of future diagnostic value, in addition to
being a therapeutical target.
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